We report the rationale and design of a community PHARMacy-based prospective randomized controlled interdisciplinary study for ambulatory patients with Chronic Heart Failure (PHARM-CHF) and results of its pilot study. The pilot study randomized 50 patients to a pharmacy-based intervention or usual care for 12 months. It demonstrated the feasibility of the design and showed reduced systolic blood pressure in the intervention group as indicator for improved medication adherence. The main study will randomize patients ≥60 years on stable pharmacotherapy including at least one diuretic and a history of heart failure hospitalization within 12 months. The intervention group will receive a medication review at baseline followed by regular dose dispensing of the medication, counselling regarding medication use and symptoms of heart failure. The control patients are unknown to the pharmacy and receive usual care. The primary efficacy endpoint is medication adherence, pre-specified as a significant difference of the proportion of days covered between the intervention and control group within 365 days following randomization using pharmacy claims data for three CHF medications (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, beta-blockers, and mineralocorticoid receptor antagonists). The primary composite safety endpoint is days lost due to blindly adjudicated unplanned cardiovascular hospitalizations or death. Overall, 248 patients shall be randomized. The minimum follow-up is 12 months with an expected mean of 24 months. Based on the feasibility demonstrated in the pilot study, the randomized PHARM-CHF trial will test whether an interdisciplinary pharmacy-based intervention can safely improve medication adherence and will estimate the potential impact on clinical endpoints.
Introduction
Chronic heart failure (CHF) affects approximately 1-2% of the adult population in developed countries and is a leading cause of morbidity and mortality. The prevalence increases with age rising to ≥10% among people >70 years of age.
1 -4 Pharmacotherapy according to the guidelines decreases morbidity and mortality in patients with heart failure (HF) with reduced ejection fraction (HFrEF) and may improve their quality of life. However, in daily practice this effect often cannot be achieved. 5 -7 Important reasons include medication non-adherence and other drug-related problems (DRPs). Non-adherence to pharmacotherapy affects 20-50% of all patients with chronic diseases. 8 -10 Poor medication adherence is associated with cognitive impairment, high complexity of the drug regimen, wrong expectations, and experienced side effects. 8, 11, 12 Reduced adherence correlates with morbidity and mortality in patients with chronic diseases including CHF.
13 -16 For example, subgroup analyses of the Candesartan in Heart failure-Assessment of moRtality and Morbidity (CHARM) study and the Systolic Heart failure treatment with the I f inhibitor ivabradine Trial (SHIFT) showed that the hazard ratio for clinical outcomes was significantly lower for patients with medication adherence >80% compared to those below 80%.
15,17
In addition to guideline-recommended medications, patients with CHF receive often pharmacotherapy for frequent co-morbidities leading to polypharmacy. 18, 19 Especially elderly patients with polypharmacy are at risk to experience DRPs like double medication, drug interactions, adverse drug reactions, or non-adherence. 20, 21 Adverse drug events and therapy failure due to DRPs are potentially preventable by interdisciplinary efforts involving pharmacists. A number of studies describing pharmacist-led or pharmacy-based interventions in patients with CHF report a reduction in hospitalizations. 22, 23 These efforts appear to be most successful when the pharmacist acted as part of a multidisciplinary team. However, the reported methodology of these studies varied widely, some studies were not sufficiently powered or assessed short time periods only. Based on the current literature, we hypothesize that structured, regular and long-term patient contacts have the potential to improve medication adherence and to detect signs of cardiac decompensation and DRPs, which may result in reduced cardiovascular hospitalizations and decreased mortality.
Pilot study
The feasibility of the planned study design including close cooperation between primary care physicians and community pharmacies was tested in a 12-month pilot study that randomized 50 patients 1:1. The inclusion criteria were age ≥ 70 years, diagnosis of CHF defined by a hospitalization for HF within the last 12 months or New York Heart Association (NYHA) dyspnoea ≥II, stable CHF medication, daily intake of four or more tablets, self-reported medication non-adherence (at least one 'yes' in the Morisky Questionnaire), and written informed consent. 24 The exclusion criteria were use of a weekly dosing aid, unwillingness or inability to visit a participating pharmacy once a week, acute cardiac decompensation, acute . coronary syndrome, recent (<3 weeks) or planned cardiac surgery, symptomatic hypotension (<90 mmHg), symptomatic hypertension (>160 mmHg), valvular heart disease > stage II, apparent liver disease (transaminases >3-fold the upper limit of normal), life expectancy <6 months, any serious co-morbid acute medical condition impairing the patient (gastrointestinal disorders, infections, exsiccosis, pain, recent surgeries), uncontrolled diabetes mellitus (blood glucose >300 mg/dL), unwillingness or inability to comply with the study protocol (including drug abuse or alcohol dependency), and participation in other studies (currently or in the last 3 months).
Patients of the intervention group received their oral medication in a weekly dosing aid in their attending pharmacy. Patients of the control group received usual care.
The primary endpoint was the feasibility of the design. Physician study visits took place at 0, 6, and 12 months (online supplementary Figure S1 ). We collected baseline data, generic and disease-specific quality of life measured by the Short Form 36 Health Survey (SF-36) and the Minnesota Living with Heart Failure (MLHF) questionnaire, respectively, the 6-min walk test, hospitalizations, and death. Blood pressure and serum lipids were assessed as indicators for medication adherence. Finally, we conducted interviews with participating pharmacists and physicians and carried out a survey among patients. The study was conducted in accordance with guidelines for clinical trials and the Declaration of Helsinki. The ethics committee of Saarland (95/2010) approved the study. Patients provided written informed consent.
Results of the pilot study
Patient characteristics and baseline medication are depicted in Tables 1 and 2 . Patients took 8 ±2 medications (inhalers and subcutaneous injections not included) per day. Half of the oral medication (4 ±1 medications) was taken for the treatment of CHF, the other half for the treatment of co-morbidities. The number of daily medications did not differ between groups throughout the study.
The main result was the general feasibility of the interdisciplinary protocol with positive feedback from the physician's offices, the pharmacies, and the patients. Two patients in the control group and two patients in the intervention group did not complete the 12-month visit for individual reasons. Satisfaction with pharmacy care was assessed by a questionnaire and increased in the intervention but not in the control group. Five patients (20%) of the intervention group decided to continue this pharmacy care after study completion with weekly dosing aids prepared by the pharmacy at their own costs.
The results of the SF-36 and the 6-min walk test did not differ between groups and between months 0, 6, and 12. The MLHF score significantly increased in the control group (23.6 ± 15.8 to 33.5 ± 5.1, P = 0.034) indicating a decrease in quality of life. In the intervention group, the score showed a trend towards increase that was not significant (28.3 ± 18.2 vs. 33.5 ± 20.6). The analysis of serum total and LDL-cholesterol showed a trend towards lower baseline measurements in the control group. During the 12-month observation, total and LDL-cholesterol significantly increased in the control but not in the intervention group. Change in systolic and diastolic blood pressures after 12 months is shown in Figure 1 . Both groups showed a trend towards improved blood pressure control. The effect was more pronounced in the intervention group with a significant and quantitatively relevant reduction of mean systolic blood pressure by 8.1 mmHg (5.9%, P = 0.025). Heart rates did not differ between groups and time-points. The exploratory analysis of hospitalizations and deaths is depicted in Table 3 .
In conclusion, the pilot study established the protocol and documented the feasibility of the novel physician-pharmacist cooperation. The protocol was well accepted by patients and the different health care providers involved. Despite the small sample, the pilot study suggests positive effects of the intervention on blood pressure and lipid control as well as HF-specific quality of life. We therefore conclude that it is reasonable to further evaluate this concept in a larger popu- 
PHARM-CHF study design
PHARM-CHF is a prospective multicentre, randomized controlled study.
Patients and follow-up
Elderly patients aged ≥60 years with CHF will be randomized. CHF is defined by HF symptoms, current treatment with diuretics, and a hospitalization for HF within the last 12 months or increased B-type natriuretic peptide (BNP; ≥350 pg/mL) or N-terminal pro-B-type natriuretic peptide (NT-proBNP; ≥1400 pg/mL) concentrations. Patients with CHF are eligible across the spectrum of different left ventricular ejection fractions (LVEF). Inclusion and exclusion criteria are listed in Table 4 . The mean follow-up is expected to be 24 months with a minimum of 12 months. 
Study aims
The aim of PHARM-CHF is to investigate whether a continuous interdisciplinary intervention improves medication adherence (primary efficacy endpoint) and leads to a reduction in hospitalizations and mortality (primary safety endpoint) in elderly patients with CHF. 
Ethical considerations
The PHARM-CHF trial is registered with the ClinicalTrials.gov Identifier NCT01692119, conforms to the Declaration of Helsinki, 
Randomization
Eligible patients are recruited by study physicians. After choosing the attending community pharmacy, patients are assigned in a 1:1 ratio to the intervention or control group. Minimization with 20% residual randomness is used to ensure balance of the following characteristics: gender (male/female), age (<75, ≥75 years), NYHA functional class (I and II, III and IV), 9-item Patient Health Questionnaire (PHQ-9) score (<10, ≥10), diabetes mellitus (yes/no), study region (according to regional Associations of Statutory Health Insurance Physicians). A web-based randomization tool [Interdisciplinary Centre for Clinical Trials (IZKS), University Medical Center Mainz] is used allowing investigators to randomize patients via a secure web interface (www.pharm-chf.de).
Study visits and data collection
The main procedures, the timeline of the study visits, and data collected during these visits are available in the online supplementary Figure S2 and Table S1 . All patients receive usual medical care defined as the treatment of CHF at the discretion of the treating physician.
Intervention
The intervention consists of the following components: 25 ] in the community pharmacy at baseline with the aim of generating a consolidated medication plan. This includes:
• Compilation of patient's entire medication (based on physician's medication list and patient interview in the pharmacy).
• Check for DRPs such as drug interactions and double medications using a standardized checklist.
• Contact with physician to discuss problems and risks, if necessary.
Continuous intervention
• Regular (bi-)weekly visits in the pharmacy.
• Provision of medication in a weekly dosing aid.
• Discussion and counselling regarding medication, adherence, signs and symptoms of cardiac decompensation.
• Measurement of blood pressure and pulse.
• Updating the medication plan, if necessary.
• Contact with physician in case of newly detected DRPs or significant changes in vital signs.
Pharmacies are not paid through existing mechanisms, as this service is currently not reimbursed by the sick funds in Germany and, hence, not part of 'usual care'. Patients already receiving the service of weekly dosing aids were not eligible for the study.
Standardization
Participating pharmacists and physicians were trained either by telephone, on site or during a workshop about study-specific aspects. They received standardized material including study guidelines, checklists and forms, the study protocol, study material, information about the electronic case report form (eCRF), and a contact list. A telephone hotline as well as a website (www.pharmchf.de) was available as information source and for requests. If necessary, questions were forwarded to the study personnel or the principal investigators. Medication was dose-dispensed based on the recommendations of the Federal Chamber of Pharmacists (BAK), i.e. by dual control. A Standard Operating Procedure (SOP) of the BAK for the measurement of blood pressure and pulse in the pharmacy was made available to all intervention pharmacies. Monitoring visits were conducted by the IZKS in the medical practices. Monitoring was done either by visits of a clinical monitor or by telephone contacts according to a SOP. The monitor checked the informed consent forms and reviewed the entries into the eCRF on the basis of source documents. The physician allowed the monitor access to all essential documents and provided support. The IZKS assisted the physician to conduct the study according to the protocol as well as regulatory and ethical requirements. Moreover, pharmacists were assisted to conduct the study according to the protocol by study personnel of the ABDA.
Medication review
Patients in the intervention group undergo a structured medication review including a patient interview at the participating pharmacy within 2 weeks after randomization. For the preparation of the interview, the pharmacy receives the medication documented by the physician during the baseline visit via an eCRF. In addition, the pharmacist asks the patient to bring the entire medication currently taken, including non-prescription (over the counter) drugs, to this appointment. During the interview, the pharmacist documents all medicines currently taken by the patient, the dosage and the application time according to the information given by the patient. In addition, potential side effects and (potential) administering and adherence problems are documented.
After the interview, the pharmacist checks for DRPs based on the patient interview, the medication dispensing history available in the pharmacy, and the medication plan provided by the medical practice. A checklist summarizing DRPs is used by the pharmacist to ensure a standardized approach. 
Continuous intervention
The continuous intervention consists of regular pharmacy visits (weekly or bi-weekly). It includes structured counselling and the supply with pharmacy-filled weekly dosing aids.
Dosing aids
The pharmacy chooses the type of weekly dosing aid together with the patient. The dosing aid contains all medications in a dayand time-specific manner for one week and is clearly labelled with information regarding the patient, contents and contact information of the pharmacy. The pharmacy prepares the weekly dosing aid of the patient based on an up-to-date medication plan. The physician's office or the patient informs the pharmacy about a change in medication. Furthermore, the pharmacist asks at every visit about potential changes. The preparation follows the recommendations of the Federal Chamber of Pharmacists. 26 Newly prescribed medication that is indicated immediately (e.g. an antibiotic) is taken by the patient in addition to the dosing aid. In general, changes in the medication are included in the weekly dosing aid whenever the next aid is due. With every change, the pharmacist checks for DRPs, contacts the physician if necessary and updates the online medication plan. The pharmacist documents potential DRPs discussed with the physician as well as DRPs which are solved directly by the pharmacist.
Pharmacy visit
The patient visits the pharmacy once a week to collect the medication in a weekly dosing aid. The pharmacist provides the patient with information about the medication and motivates the patient to take the medication, to self-manage symptoms and weight changes (e.g. keeping a weight diary). During these weekly visits, the pharmacist inquires after potential side effects, medication adherence, as well as signs and symptoms of a potential cardiac decompensation (e.g. shortness of breath). The pharmacist measures blood pressure and pulse. If significant changes in vital signs are detected or if the patient reports relevant symptoms or signs (e.g. a significant weight increase), the pharmacist contacts the physician or recommends the patient to contact his physician. If the patient does not collect his medication, the pharmacy contacts first the patient. In case of difficulties, the pharmacy contacts the physician's office additionally.
Adoption of the intervention
Once the patient has attended the weekly visits in the pharmacy for a minimum of 4 continuous weeks and if needed, the patient and his pharmacist can agree on bi-weekly visits to the pharmacy.
When a patient cannot visit the pharmacy (e.g. the patient is ill/home-bound), the pharmacy can either deliver the weekly dosing aid to the patient's home. If the patient is absent for longer than a week (e.g. on holiday), the pharmacy can supply the patient with more than one weekly dosing aid. As the pharmacy visit is an essential part of the intervention, it is very important that the patient visits his pharmacy regularly. The supply of weekly dosing aids for more than 2 weeks will be limited to these exceptions.
Usual care group
Patients in the control group continue to visit pharmacies of their choice to fill prescriptions. Participating pharmacies are not informed about the enrolment of patients in the control group.
Blinding
As in all behavioural trials, double blinding is impossible. However, and in contrast to other studies, in PHARM-CHF only the patients randomized to the intervention group are known to the pharmacies, avoiding contamination. Instead of cluster-randomizing pharmacies and their patients, patients are randomized by the recruiting physician on an individual level. All other investigators, committees, and staff remain fully blinded throughout the study to the randomization status of the patients.
Clinical event adjudication
A blinded Clinical Event Committee (CEC) will adjudicate all hospitalizations occurring after randomization according to pre-specified criteria in the CEC charter. Adjudicated events will be categorized by their cause and divided into cardiovascular and non-cardiovascular (online supplementary Appendix S4).
Study endpoints
The primary efficacy endpoint is adherence to medication, pre-specified as a significant difference between the intervention and control group using pharmacy claims data for three CHF medications [angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (ACEi/ARB), beta-blockers (BB), and mineralocorticoid receptor antagonists (MRA)] prescribed at baseline.
Medication adherence will be calculated based on the proportion of days covered (PDC) during the 365 days following randomization, adjusted for inpatient days, medication switches, medication fills prior to randomization, and death. In case of inpatient days, the proportion will be adjusted by excluding days from both the numerator and denominator and assuming that patients did not deplete their medication on their medication supply on those excluded days. If a patient switches medications within a class (including ACEi/ARB), the patient's medication supply will be replaced with the new medication supply. If a patient dies, all days following the death will be excluded. Existing medication at randomization (=day 1) will be captured, but only the days during the 365-day follow-up will contribute to the final proportion.
. Adherence for each medication class prescribed will be calculated and can range from 0 to 1.0 (perfect adherence) and will then averaged across all non-missing classes of medications to derive the summary PDC. There are almost no data that provide accurate estimates of the impact of changing adherence on clinically relevant outcomes in CHF. We conservatively assume an improvement of the summary PDC ≥10% in the intervention group compared to usual care as clinically relevant. 27, 28 We will additionally analyse the PDC for each drug class (ACEi/ARB, BB, MRA), percentage of patients with a mean PDC ≥80% (=adherent), and percentage of patients with a PDC ≥80% for each drug class (sensitivity analyses for a cutpoint ≥88%).
29
Other secondary efficacy endpoints after 1 year include quality of life, depression, and patient global assessment. Quality of life is measured by the MLHF questionnaire. 30 -32 The MLHF questionnaire is specific for CHF and has 21 questions with scores ranging from 0 to 105: higher scores indicate worse quality of life; minimal clinically important difference, 5 points, assessed by the patients at the day of their appointment with their physician at baseline and after 12 months. A score of <24 signifies a good, a score between 24 and 45 signifies a moderate, and a score > 45 signifies a poor quality of life. 33 Depression is common in CHF and associated with adverse clinical outcomes. Depression will be assessed using the PHQ-9. The self-reported patient global assessment scale consists of a simple judgement indicating improvement, no change, or worsening since the start of the study. 34 -37 The primary composite safety endpoint is all-cause mortality or unplanned cardiovascular hospitalizations as days lost due to unplanned cardiovascular hospitalizations or death. Secondary exploratory safety endpoints are all-cause mortality or unplanned cardiovascular hospitalizations as recurrent event (number), unplanned cardiovascular hospitalizations (recurrent event, number), unplanned hospitalizations for HF (recurrent event, number), days lost due to hospitalizations of any cause or death, unplanned all-cause hospitalizations, and all-cause mortality.
Sample size
Assuming a mean PDC in the year before randomization of approximately 0.7, a sample size of 176 patients (88/group) is needed to detect a 10% (standard deviation 22%) improvement of the mean PDC between the intervention and the usual care group with a power of 85% and an alpha of 5%. Assuming a dropout and lost to follow-up of 30%, 248 patients have to be enrolled in the study.
Statistical analyses

Study population
The intention-to-treat (ITT) population consists of all patients who have post-baseline data available and who did not fail to satisfy major entry criteria. Patients in the intervention arm for whom no consolidated medication plan is available-that is, subjects that failed to comply with the study protocol at entry (i.e. did not undertake the medication review at the pharmacy-which is comparable of not taken any trial medication), with or without withdrawal of consent, have no post-baseline data available. The per-protocol population consists of all subjects of the ITT population who completed the study without major protocol violations-that are violation of inclusion criteria, meeting exclusion criteria, post-baseline data not available, consolidated medication plan not available (intervention group patients only) and premature termination (except death).
Subgroup analyses (pre-specified)
Exploratory subgroup analyses will be performed for the primary efficacy and safety endpoints and selected secondary efficacy (PDC for each drug class and mean PDC ≥80%) and safety endpoints [all-cause mortality or unplanned cardiovascular hospitalizations as recurrent event (number), unplanned cardiovascular hospitalizations (recurrent event, number), and all-cause mortality] to assess the consistency of intervention effects across the following subgroups of interest: age (60-74 vs. ≥75 years), sex, NYHA class (I/II vs. III/IV), LVEF (<40% vs. ≥40%), level of illness burden (cut-off median co-morbidities and number of different drugs at baseline), history of diabetes mellitus, history of depression (cut-off PHQ-9 score < 10 vs. ≥10), heart rate at baseline (≤75 vs. >75 b.p.m.), HF medication at baseline: BB vs. BB plus ACEi/ARB and BB plus ACEi/ARB vs. BB plus ACEi/ARB plus MRA, time between last HF hospitalization and randomization (≤3 vs. >3 months), and quality of life at baseline (cut-off median).
Study status
In total, 258 patients have been recruited by January 2016 and 130 randomized into the intervention and 128 into the control group. In total, 31 study centres (family physicians/general practitioners, internal medicine specialists, and both office-and hospital-based cardiologists) and 69 community pharmacies in different parts (States) of Germany are taking part (online supplementary Appendix S3).
Discussion
Poor medication adherence represents a major problem and at the same time a major opportunity to improve outcomes in patients with CHF. However, convincing evidence for effective interventions addressing adherence from prospective, randomized and long-term studies is missing.
Several systematic reviews have sought to identify the most effective interventions for improving medication adherence. 38, 39 Despite differences in methodologies, the conclusions have been consistent: only comprehensive interventions, which combined several different elements, have the potential to improve adherence. Poor adherence cannot be 'cured'; it decreases again after stopping interventions to improve adherence. Therefore, a continuous strategy is needed. Interdisciplinary patient care may provide an opportunity to improve medication adherence in patients with CHF. 39 For example, a pharmacist care programme combining education and counselling with the preparation of medicines in a weekly dosing aid led to increased medication adherence. 41 This improvement was associated with improved blood pressure and lipid values. However, clinical endpoints, such as hospitalizations or mortality, have not been assessed. 41 In addition to medication adherence, compliance with other lifestyle recommendations may improve the outcome in CHF. Rapid weight gain as well as deterioration of symptoms are early indicators of a cardiac decompensation. Adherence with weight monitoring was found to be associated with a lower mortality. 42 It is recommend that patients with CHF should weigh themselves regularly and record their weight in a diary. However, similar factors contribute to reduced adherence with medication and self-control. CHF patients frequently either do not monitor weight and symptoms or do not recognize the signs. 43, 44 Interventions improving medication adherence might also be effective to improve adherence with symptom monitoring. 45 No treatment has yet been shown convincingly to reduce morbidity or mortality in patients with HF with preserved (HFpEF) or mid-range ejection fraction (HFmrEF). Despite this fact, patients with CHF are eligible to participate in the study across the spectrum of LVEF. The evidence that diuretics improve symptoms is similar across the spectrum of LVEF. 2 Use of a diuretic was therefore defined as an inclusion criterion. CHF patients in the ambulatory setting are complex because they have a high burden of cardiovascular and non-cardiovascular co-morbidities, which may influence prognosis more than the ejection fraction. 46 Regardless of LVEF, patients hospitalized with HF have a similarly survival with an elevated risk for cardiovascular and HF readmission. 47 Patients with HFpEF account for approximately 50% of all hospital admissions for HF. Moreover, the current use of medication is very similar for patients with HFrEF, HFmrEF, and HFpEF. 46 There is, to the best of our knowledge, no evidence suggesting that patients with HFpEF/HFmrEF differ in the extent of medication non-adherence compared to patients with HFrEF. Since our study addresses the care of ambulatory patients with CHF with an intervention based in community pharmacies, we believe that inclusion of HFpEF/HFmrEF patients is needed to reflect current ambulatory practice. regular practice nor reimbursed by health insurance companies. Finally, the study is not powered to show superiority with regard to mortality or cardiovascular hospitalizations.
The PHARM-CHF study is the first randomized controlled trial investigating the effect of a structured pharmacy-based interdisciplinary programme using regular contacts with the local pharmacy and weekly dosing aids compared to usual care on medication adherence in patients with CHF. The study will collect data on CHF mortality and morbidity as safety endpoints. The novel intervention applied is interdisciplinary, addresses several important components of pharmacotherapy and symptom control and-importantly-is continuously provided. Pharmacists and physicians will cooperate with the aim to improve medication adherence, prevent and solve DRPs, and improve the monitoring of symptoms. If the data of the pilot study are confirmed, PHARM-CHF will provide novel evidence on the management of CHF that may be important for a large number of patients and many health care professionals. Furthermore, if proven to be effective for elderly patients with CHF, the concept may be of value to improve medication adherence in other populations with polypharmacy. study. Appendix S3. List of study centres and investigators of the PHARM-CHF study. Appendix S4. Event classification criteria for Clinical Event Committee. Figure S1 . Pilot study diagram. Figure S2 . Timeline of the study visits and main procedures of PHARM-CHF. Table S1 . PHARM-CHF study visit schedule and data collection.
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